drugset / Trial / NCT04085289
A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The purpose of this study is to assess how fast galcanezumab gets into the blood stream and how long it takes the body to remove it. Information about side effects will be collected. The study is open to healthy Chinese participants. It will last up to about 24 weeks.
Timeline
- Start
- 2019-11-20
- Primary completion
- 2020-05-21
- Completion
- 2020-05-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galcanezumab | Monoclonal antibody | 120 mg | Subcutaneous |
| Subject | Galcanezumab | Monoclonal antibody | 240 mg | Subcutaneous |
Indications
No indication recorded.